SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Betz Stephen F.

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

10222 BARNES CANYON ROAD, BLDG 2

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/15/2021

3. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	187,925	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	03/16/2028	Common Stock	182,370	$1.91	D
Stock Option (right to buy)	⁽²⁾	05/24/2028	Common Stock	91,185	$9.28	D
Stock Option (right to buy)	⁽³⁾	03/07/2029	Common Stock	56,250	$25.19	D
Stock Option (right to buy)	⁽⁴⁾	02/23/2030	Common Stock	60,000	$22.61	D
Stock Option (right to buy)	⁽⁵⁾	02/25/2031	Common Stock	85,000	$15.29	D
Stock Option (right to buy)	⁽⁶⁾	09/09/2031	Common Stock	15,000	$23.19	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.

2. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date; provided, however, that one-half of the shares subject to the option are subject to the further condition that they may not be exercised until the occurrence of the Issuer's initial public offering and, in the event the Issuer's initial public offering does not occur prior to the first anniversary of May 25, 2018, such portion of the stock options shall be automatically forfeited. The shares subject to the option are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.

3. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement Date of March 8, 2019.

4. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020.

5. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 26, 2021.

6. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of September 1, 2021.

Remarks:

	/s/ Marc Wilson, as attorney-in-fact	10/18/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.